Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of GASP-2 detection reagent in preparation of kit for early diagnosis and susceptibility detection of lung cancer

A detection reagent and early diagnosis technology, applied in the field of cancer diagnosis, can solve problems such as limited value of lung cancer

Pending Publication Date: 2022-05-27
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the technology for the early diagnosis of lung cancer is not yet mature, and the currently commonly used lung cancer-related tumor markers such as CEA and NSE antigens have limited value in the early diagnosis of lung cancer
There is no report about its relationship with lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GASP-2 detection reagent in preparation of kit for early diagnosis and susceptibility detection of lung cancer
  • Application of GASP-2 detection reagent in preparation of kit for early diagnosis and susceptibility detection of lung cancer
  • Application of GASP-2 detection reagent in preparation of kit for early diagnosis and susceptibility detection of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Lung cancer diagnostic kit (ELISA)

[0024] 1. Composition

[0025] (1) Pre-coated plate: 96-well plate coated with anti-human GASP-2 rabbit IgG antibody on the inner wall and bottom of the well.

[0026] (2) Enzyme-labeled antibody: (30-fold concentration) HRP-labeled anti-human GASP-2 rabbit IgG antibody.

[0027] (3) Standard product: GASP-2.

[0028] (4) Buffer: BPS containing 1% BSA, 0.05% Tween 20.

[0029] (5) Color developer: TMB substrate solution.

[0030] (6) Stop solution: 1N sulfuric acid.

[0031] 2. Use

[0032] (1) Add 0.1 mL of serum samples (standards) into the wells of the pre-coated plate, incubate at 37°C for 30 minutes, pour off the liquid in the wells, and tap 3 times to reduce liquid adhesion;

[0033] (2) Add 0.15 mL of buffer to wash the protein not bound to the pre-coated plate, repeat 5 times;

[0034] (3) Add 0.1 mL of enzyme-labeled antibody, incubate at 37°C for 30 min, pour off the enzyme-labeled antibody, and add 0.15 mL...

experiment example 1

[0040] Experimental Example 1 Clinical sample detection

[0041] 1. Method

[0042] Serum samples were collected from 980 lung cancer patients and 1010 normal people, and the content of GASP-2 in serum was detected using the kit of Example 1.

[0043] Among them: the age of lung cancer patients was 60.8±9.0 years old; by gender, there were 624 males and 356 females; by type, adenocarcinoma: 639 cases and lung adenocarcinoma: 341 cases. The normal age was 58.6±7.8 years old; according to gender, male: 612 cases, female: 398 cases; according to TNM stage, I+II stage lung cancer: 629 cases, III+IV stage lung cancer: 351 cases.

[0044] 2. Results

[0045] The level of GASP-2 in normal human serum was 4.75±1.26ng / ml, and the level of GASP-2 in serum of lung cancer patients was 31.55±5.43ng / ml (p=0.000).

[0046] In lung cancer patients, the GASP-2 content in male serum was 33.78±5.43ng / ml, and the GASP-2 content in female serum was 30.87±4.43ng / ml (p=0.236); the serum GASP-2 co...

experiment example 2

[0051] Experimental Example 2 Serum GASP-2 Concentration and Diagnosis Tracking of Lung Cancer High Risk Population

[0052] 1. Method

[0053]The serum GASP-2 concentration of the high-risk lung cancer population (1233 cases) and the control population (899 cases) in the high-risk lung cancer site was continuously detected for 5 consecutive years, and lung cancer was diagnosed by conventional lung cancer diagnostic methods such as medical imaging.

[0054] Note:

[0055] High incidence of lung cancer, that is, areas with high incidence of lung cancer, in this case, Xuanwei, Gejiu, Yunnan;

[0056] Lung cancer high-risk groups meet the following conditions: 1. Age: ≥45 years old; 2. Smoking history: smoking ≥20 pack-years; 3. Family history of cancer: long-term exposure to environmental carcinogens.

[0057] 2. Results

[0058] At the end of the 4-year follow-up study period, a total of 128 people in the high-risk group in the high-risk group of lung cancer were diagnosed w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a GASP-2 detection reagent in preparation of a kit for early diagnosis and susceptibility detection of lung cancer, and belongs to the field of cancer diagnosis. In serum of a lung cancer patient, the content of GASP-2 is obviously higher than that of normal people. According to the early diagnosis kit for the lung cancer, the lung cancer can be rapidly and accurately diagnosed by detecting the content of GASP-2, and the early diagnosis rate of the lung cancer can be increased, so that the prognosis of a patient with the lung cancer is greatly improved, and the disease burden of the lung cancer is reduced.

Description

technical field [0001] The present invention belongs to the field of cancer diagnosis. Background technique [0002] Lung cancer is the malignant tumor with the fastest growing morbidity and mortality in the world, with more than 2 million new cases of lung cancer every year. Lung cancer is the malignant tumor with the highest morbidity and mortality in my country. Every year, there are nearly 800,000 new lung cancers in China, and nearly 700,000 people die. The incidence of lung cancer in my country accounts for 37.9% of the world's lung cancer incidence, and the mortality rate accounts for 39.4% of the world's lung cancer deaths. The US SEER database shows that more than half of lung cancer patients are locally advanced or with distant metastasis at the time of diagnosis. [0003] At present, the technology for the early diagnosis of lung cancer is not yet mature, and antigens such as CEA and NSE, which are commonly used in clinical practice, are of limited value in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574
CPCG01N33/57423G01N33/57488
Inventor 周清华梁好许峰邓汉宇范雪娇
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com